# NephroDI Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nephrodi-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.nephrodi.com
- Total disclosed funding: $2M
- Latest round: Series A (Jun 11, 2024)
- Investors on record: 1

## About

Based in Pennsylvania, US, and founded in 2017 by Ish Khanna, Janet D. Klein, Jeff M. Sands, and Ram Pillarisetti, NephroDI Therapeutics, Inc. is a pharmaceutical company developing an oral drug to treat Nephrogenic Diabetes Insipidus (NDI) in children. As of 2022, Rachael Hagan is the CEO of the company. In May 2021, NephroDI Therapeutics raised USD 1.6 million in seed funding from Xontogeny, LLC.

The company is developing NDI-5033, which is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output for the treatment of Nephrogenic Diabetes Insipidus (NDI).

## Funding rounds

- Series A, Jun 11, 2024, $2M — Sound Bioventures

## Investors

- Sound Bioventures (https://capitalatlas.ai/funds/sound-bioventures) — Series A